Dear Sir,
It is now 26 years since the introduction of the Wescor Macroduct system for the collection of sweat and measurement of conductivity. The collection system has been widely adopted due to its ease of use and maintenance. Although conductivity measurement is simple and robust it has not been so widely adopted as conductivity measurements alone are not recommended for diagnosis of cystic fibrosis in the UK 1 or USA. 2 A recent report in this journal 3 highlights the use of conductivity as a screening test in the Australian guidelines; any patient with a sweat conductivity result greater than 50 mmol/L NaCl eq. should be followed up with chloride measurement, either on the existing sweat sample or on a fresh collection.
Over the years many groups have attempted to compare the diagnostic performance of sweat conductivity and chloride concentrations. We have collected comparison data over two years which is shown in Figure 1 ; all samples with detectable sweat chloride concentrations, including repeat samples, are included. Our data are remarkably similar to that previously published; showing closer agreement of conductivity and chloride results in the cystic fibrosis patients compared with the unaffected patients ( Figure 1a ) 4 and a second-order polynomial giving a line of best fit 5 ( Figure 1b ). In common with others we have very few results in the intermediate region. The only sample with an intermediate chloride concentration was from the unaffected sibling of a cystic fibrosis patient; genetic testing has not been performed to define carrier status. Genetic testing of the other patients with intermediate conductivity results failed to identify any of the 32 most common cystic fibrosis mutations. The reluctance in the literature to use conductivity measurements for diagnosis of cystic fibrosis is based on sensitivity and specificity calculations. However, the fact that conductivity and chloride measurements may differ in their ability to identify individual patients in the intermediate range is only to be expected. These patients are comparatively rare and will always pose a diagnostic challenge even when using sweat chloride quantitation. The diagnosis of cystic fibrosis in any patient will involve clinical examination and genetics as well as biochemistry.
Chloride measurements may be subject to pipetting, weighing and calculation errors as methods are adapted to handling very small samples. The sample is usually consumed during chloride analysis. In contrast, the Wescor SweatChek analyser is designed to measure the conductivity of small sweat samples directly without dilution and the sample may be recovered after analysis. It is our view that sweat conductivity can play a role in the diagnosis of cystic fibrosis and its measurement should be incorporated into the next version of the UK guidelines.
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Competing interests: None. Funding: None. Ethical approval: Not required. Guarantor: EH. Contributorship: EH collected and analysed results, prepared manuscript and RL approved the manuscript. Firstly, their description of 'the NHS Bowel Cancer Screening Programme' is inaccurate: it is applicable only to England. Health is a devolved matter and the four countries of the UK have different approaches. The Scottish Bowel Screening Programme began in 2007 and is now fully rolled out, inviting all 50-74 y olds biennially using a two-tier reflex strategy. 2, 3 Secondly, their experiment to determine 'sensitivity', i.e. the analytical detection limit (ADL) is flawed. Their basic assumption is that an 'occult blood-negative' sample contains no peroxidase activity (expressed as mg Hb/g material, not mg/Hb/g). Testing as negative with hema-screen FOBT (Alpha Labs Ltd, Eastleigh, Hants, UK) does not mean that there is no such material present: it simply shows that the concentration is below the ADL. Thus, if material with x mg Hb/g was added to a base sample with any material present, but with concentration less than the ADL, the final concentration would not simply be x mg Hb/g as assumed, 1 but lower. Thus, the true ADL for hema-screen must be less than the 0.7 mg Hb/g suggested. 1 Indeed, for a dichotomous test such as FOBT, the ADL is not the lowest concentration that gives a positive result 100% of the time but that which gives 50% negative and 50% positive results. This is superbly demonstrated in the Yorkshire External Quality Assessment Scheme. For each challenge, the percentages of positive and negative results found are reported. The challenge of 9 November 2009, with 1.2 mg Hb/g matrix, had 17.2% negative and 82.8% positive results. In contrast, the challenge of 21 December 2009, with 0.2 mg Hb/g matrix, had 83.6% negative and 16.4% positive results. If over a range of concentrations, the percentage positive was plotted on the ordinate against concentration on the abscissa, the resulting relationship would rise: if the percentage negative was similarly plotted, the relationship would fall. The concentration at which the relationships intersect is the true ADL. For hema-screen, using this objective approach, 4 the ADL is 0.6 mg Hb/g and not 0.7 mg Hb/g as suggested. 1 Thirdly, it was stated 1 that 'while newer, more specific and more sensitive immunoassays are becoming available, these are more expensive so that the conventional colorimetric tests will remain for some time'. Guaiac-based FOBT have so many disadvantages that they should now be considered obsolete. 5 Newer faecal immunochemical tests (FITs) are specific for intact haemoglobin and its early degradation products and have many advantages. 5 They are not subject to interference from dietary constituents, are clinically more specific for bleeding in the colon and rectum, require less than the two samples from three stools needed for FOBT and generally have more userfriendly collection devices. They are used in many modern screening programmes and advocated in many guidelines. Although important, cost should not be the overriding consideration in selection of laboratory tests.
Fourthly, the only evidence for use of FOBT is in screening programmes. 5 No evidence-based guideline on investigation of lower gastrointestinal tract disorders advocates use of FOBT. Moreover, there are significant welldocumented preanalytical problems in the collection, transport and handling of samples for FOBT. 5 A number of laboratories in the UK have already eliminated FOBT from their repertoires 6 and have actively discouraged use of FOBT in wards, clinics and primary care. I strongly suggest that the laboratory community follow these laudable examples. Then, of course, concerns about poor performance in EQAS would not exist and time and resources would not be wasted undertaking inconclusive studies. In the few clinical situations in which investigation for the presence of blood in faeces would possibly be helpful, including the detection of human faecal blood in the paediatric setting, investigation of symptomatic individuals when bowel visualization is difficult or impossible, follow-up of those with established disease, and in the investigation of familial colorectal cancer, I strongly suggest that FIT should be used.
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